scispace - formally typeset
J

Jana Pachlopnik Schmid

Researcher at Boston Children's Hospital

Publications -  62
Citations -  3740

Jana Pachlopnik Schmid is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Medicine & Hemophagocytic lymphohistiocytosis. The author has an hindex of 23, co-authored 51 publications receiving 2835 citations. Previous affiliations of Jana Pachlopnik Schmid include Necker-Enfants Malades Hospital & University of Zurich.

Papers
More filters
Journal ArticleDOI

2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative

TL;DR: Criteria for the classification of macrophage activation syndrome (MAS) in patients with systemic juvenile idiopathic arthritis (JIA) is developed.
Journal ArticleDOI

Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects

Charlotte Schwab, +84 more
TL;DR: The penetrance, clinical features, laboratory values, and outcomes of treatment options were assessed in a worldwide cohort of CTLA4 mutation carriers, finding affected mutation carriers with CTLA‐4 insufficiency can present in any medical specialty.
Journal ArticleDOI

2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis

TL;DR: A set of classification criteria for MAS complicating systemic JIA is developed and preliminary evidence of its validity is provided, which will potentially improve understanding of MAS in systemic Jia and enhance efforts to discover effective therapies, by ensuring appropriate patient enrollment in studies.
Journal ArticleDOI

X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management, and outcome of the disease

TL;DR: A large cohort of 91 genetically defined XLP1 patients are described and characteristics and outcome data for 43 patients receiving hematopoietic stem cell transplant (HSCT) and 48 untransplanted patients are reported.